Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense approaches in prostate cancer.

Kim N Chi1, Martin E Gleave

  • 1BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada. kchi@bccancer.bc.ca

Expert Opinion on Biological Therapy
|June 4, 2004
PubMed
Summary

Antisense oligonucleotides offer a promising new therapy for hormone refractory prostate cancer by targeting specific genes involved in cancer progression. This approach is particularly useful when other treatments are ineffective.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Future oncology (London, England)·2026
Same author

Cell-free DNA in prostate cancer and treatment selection.

Expert review of anticancer therapy·2026
Same author

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Future oncology (London, England)·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hormone refractory prostate cancer lacks effective treatment options, necessitating novel therapeutic strategies.
  • Understanding molecular pathways driving prostate cancer progression has revealed numerous gene targets.
  • Antisense oligonucleotides (ASOs) represent a targeted gene inhibition technology.

Purpose of the Study:

  • To review the current status and future potential of antisense oligonucleotides for prostate cancer therapy.
  • To identify key gene targets amenable to antisense oligonucleotide intervention in prostate cancer.

Main Methods:

  • Review of scientific literature on antisense oligonucleotides and prostate cancer molecular targets.
  • Analysis of genes implicated in prostate cancer progression, including apoptosis, growth factors, cell signaling, and androgen receptor (AR).

Main Results:

  • ASOs can specifically inhibit gene expression by binding to complementary mRNA.
  • Several gene targets, including BCL-2, clusterin, IAP family, MDM2, and AR, are being investigated for ASO therapy.
  • ASO therapy shows promise for genes whose products are not targeted by small molecules or antibodies.

Conclusions:

  • Antisense oligonucleotides hold significant therapeutic promise for hormone refractory prostate cancer.
  • Targeting specific genes involved in cancer progression offers a viable treatment modality.
  • Further research and clinical development of ASOs are warranted for prostate cancer.

Related Experiment Videos